Wholly-Owned Subsidiary of China Health Industries Holdings, Inc. Signed an OEM Contract

HARBIN, CHINA / ACCESSWIRE / April 19, 2016 / Harbin Humankind Biology Technology Co., Limited (“Humankind”), the wholly-owned subsidiary of China Health Industries Holdings, Inc. (OTCQB: CHHE) (“China Health Industries” or “company”), signed a long-term OEM contract with Yantai Baobei Biotech Limited (“Baobei”) in April, 2016. According to the OEM contract, Humankind is pointed as the original equipment manufacturer of health food for Baobei. The contract will be valid since April, 2016, and the estimated cumulative processing fee is 500,000 US dollars within one year, accounting for about 5% of fiscal 2015 revenue.

CEO of China Health Industries, Xin Sun explains: “Providing OEM service to Baobei is not only effectively utilization of our productivity, but also demonstration of our excellent equipment quality. The most important thing is it brings new growth point of profit. Our company is negotiating with other companies in Chinese pharmaceuticals industry about OEM agreements. We estimate it brings 500,000 to 1,000,000 US dollars as OEM processing fee within one year, accounting for about 5%-10% of fiscal 2015 revenue.”

Mr. Sun further explains: “Health food and drug products are the main source of our sales revenue. Our next step is to increase investment in development of anti-cancer drugs, genetic testing and stem-cell therapy. Our goal is to provide a closed loop ecosystem in health-care industry, which is built up with high-quality health products, drug development, health management and medical treatment for our customers.”

About Us

China Health Industries Holdings, Inc. (www.chinahealth.tech) produces, markets and distributes high-quality medicines, health products, health devices and cosmetics. The Company routinely posts important information on its website.

CHHE owns GMP-certified plant and facilities and manufactures 21 CFDA-approved medicines and 14 CFDA-approved health supplement products in soft capsule, hard capsule, tablet, granule and oral liquid forms. These products address key major markets, including women’s products, geriatric products, children’s products and other vital market sectors.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:

Company:

Mr. Xin Sun
Chairman & CEO
China Health Industries Holdings, Inc.
Tel: 86-451-88100688
Email: chhe_ir@163.com

SOURCE: Harbin Humankind Biology Technology Co., Limited

ReleaseID: 438978